<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in Africa may be curable by chemotherapy alone; in nonendemic regions results are reportedly less favorable </plain></SENT>
<SENT sid="1" pm="."><plain>Fifty-four Americans with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were treated with two sequential combined treatment regimens that incorporated therapeutic approaches from clinical trials in Africa </plain></SENT>
<SENT sid="2" pm="."><plain>Four patients died during induction therapy, and 48 of the remaining 50 achieved complete remissions </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-two relapsed at a median of three months from the start of therapy </plain></SENT>
<SENT sid="4" pm="."><plain>The overall two-year actuarial survival was 54 percent: younger patients ( less than 12 years old) and patients with minimal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden (stages A, B and AR) had significantly better survivals than older patients (P less than 0.02) and patients with advanced <z:e sem="disease" ids="C0000735" disease_type="Neoplastic Process" abbrv="">abdominal tumors</z:e> (stages C and D) (P less than 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>No differences in survival were detected between patients treated at the National Institutes of Health and those treated in regional institutions on either protocol </plain></SENT>
<SENT sid="6" pm="."><plain>Complete response rates, relapse frequency and survival in American patients are similar to results in Africa </plain></SENT>
</text></document>